

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
30 September 2021 (30.09.2021)



(10) International Publication Number
WO 2021/193984 A3

(51) International Patent Classification:

C07K 14/605 (2006.01) A61P 1/08 (2006.01)
A61K 38/00 (2006.01) C12N 15/00 (2006.01)

(21) International Application Number:

PCT/JP2021/014423

(22) International Filing Date:

25 March 2021 (25.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/994,716 25 March 2020 (25.03.2020) US

(71) Applicant: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, 541-0045 (JP).

(72) Inventors: **HENNINOT, Antoine, Charles, Olivier**; c/o Takeda California, Inc., 9625 Towne Centre Way, San Diego, CA 92121 (US). **COLE, Derek, Cecil**; c/o Takeda California, Inc., 9625 Towne Centre Way, San Diego, CA 92121 (US). **SCORAH, Nicholas**; c/o Takeda California, Inc., 9625 Towne Centre Way, San Diego, CA 92121 (US).

(74) Agent: **UMEDA, Shinsuke** et al.; Ohno & Partners, Marunouchi Kitaguchi, Building 21F, 6-5, Marunouchi 1-chome, Chiyoda-ku, Tokyo, 1000005 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: QD DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF

(57) Abstract: The present disclosure provides GIP receptor agonist peptide compounds suitable for once per day dosing (QD), said peptide compounds having an activating action on GIP receptors and use of the GIP receptor agonist peptide as a medicament for the treatment and/or prevention of emesis, or a symptom or condition associated with emesis. Specifically, a GIP receptor agonist peptide containing a sequence represented by any of the formulas (I)-(V) or a salt thereof, and a medicament comprising the same are provided.

WO 2021/193984 A3